The board of directors of SSY Group Limited announced that the National Medical Products Administration ofChina has approved the addition of 50ml:4.2g specification and passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Sodium Bicarbonate Injection. Sodium Bicarbonate Injection is mainly used in the treatment of metabolic acidosis, alkalinization of urine, treatment of symptoms caused by hyperacidity and treatment of intravenous intoxication by certain drugs.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.22 HKD | -1.40% |
|
-6.22% | -14.57% |
28/06 | SSY Group Gets Registration Approvals for 2 Drugs in China | MT |
28/06 | SSY Group Limited Announces Update on Product Development | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.57% | 160.46Cr | |
+55.32% | 82TCr | |
-6.75% | 35TCr | |
+13.56% | 31TCr | |
+10.68% | 30TCr | |
+16.57% | 24TCr | |
+2.04% | 22TCr | |
+13.31% | 22TCr | |
+8.48% | 17TCr | |
-2.81% | 16TCr |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Announces Update on Product Development